AZILSARTAN AMELIORATES VENTRICULAR HYPERTROPHY BY REDUCING OXIDATIVE STRESS IN OVARIECTOMIZED RATS

CASCALLARES, ENZO; RUAU, SOFIA; GUTIERREZ, ALVARO; VELEZ RUEDA, JORGE OMAR; MARTINEZ, VALERIA ROMINA; DE GIUSTI, VERÓNICA

Mar del Plata

Congreso; REUNIÓN CONJUNTA SAIC SAI&FAIC SAFIS 2022; 2022

Sociedad Argentina de Fisiología

Background. Cardiovascular disease is the leading cause of death in postmenopausal women. Estrogen deficiency is associated with increased oxidative stress, which can contribute to left ventricular dysfunction. The novel potent angiotensin receptor blocker azilsartan (AZIL) developed for hypertension treatment, may improve the cardiac function in ovariectomized rats (OVX), by reducing the formation of reactive oxygen species (ROS). In this study, we analyze the effect of AZIL on cardiovascular damage during menopause. Methods. Spontaneously hypertensive rats (SHR) (female, 16-weeks-old, 180-200g) were sham-operated or bilateral ovariectomized (SHR-OVX). SHR-OVX rats were randomly divided in 2 groups: no-treated (control), treated with 10 mg/kg/day of AZIL in drinking water for 6 weeks. Systolic blood pressure, cardiac hypertrophy indices and oxidative stress in isolated cardiomyocytes were measured. Results (n=4 per group) were analyzed by ANOVA (*p